ArticleAntibiotics (Basel, Switzerland)2026
Synthesis and In Vitro Biological Evaluation of Amphiphilic Derivatives of Carvacrol as Potent Antibacterial Agents.
Article in Antibiotics (Basel, Switzerland), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
BACKGROUND/
objectivesThe rapid emergence and spread of antibiotic-resistant bacterial strains represent a major global health threat, requiring the development of novel broad-spectrum antimicrobial agents. This study aims to design, synthesize, and evaluate a novel series of multitarget amphiphilic carvacrol derivatives to combat molecular resistance mechanisms by combining a natural monoterpene with polycationic ribonuclease scaffolds.
methodsA series of 16 dimeric carvacrol-1,4-diazabicyclo[2.2.2]octane (DABCO) hybrids, including both novel and previously reported derivatives, with varying central and lateral linkers were synthesized. In vitro antibacterial activity was evaluated against Gram-positive (
resultsSeveral compounds exhibited potent antibacterial activity, with MIC values ranging from 4 to 63 µM against most strains. The most active hybrid, DL4CAR-6, demonstrated broad-spectrum efficacy (MIC 4-16 µM against most strains) and outperformed the reference amphiphile DL4-12 against
conclusionsThe newly developed carvacrol-DABCO amphiphilic hybrids represent a promising class of multitarget antibacterial agents. Their broad-spectrum efficacy, bactericidal kinetics, RNA-cleaving activity, low hemolytic toxicity, and favorable selectivity indices support their potential for further in vivo evaluation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.